Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2016

View Archived Issues

Mitsubishi Tanabe profiles pipeline progress of second quarter of fiscal 2016

Lundbeck updates key developments of third quarter 2016

AZD-8931 does not improve progression-free survival in wild-type colorectal cancer patients

NIH award supports TherapyX's testing of IL10-NanoCap

NICE recommends Eisai's eribulin for breast cancer

Ascend Biopharmaceuticals reports interim results of phase I/IIa study on ASN-002

Study finds pharmacokinetic equivalence between Neulasta pegfilgrastim and Mylan/Biocon biosimilar

FDA accepts BLA for human rabies immunoglobulin

First-in-human study of Mucosis' SynGEM begins

GeoVax and ViaMune to codevelop cancer immunotherapy program

The Medicines Company discontinues development of MDCO-216

Amgen presents pipeline highlights of third quarter 2016

Vertex Pharmaceuticals reports positive phase III results on Orkambi

CHERISH study of Spinraza in later-onset SMA meets primary endpoint

TGFB1 may be behind coronary artery disease with glatiramer acetate treatment

FDA grants several orphan drug designations to APX-001

Scientists develop a new animal model for BBSOAS

H. Lundbeck patents PDE1 inhibitors

Guangdong Zhongsheng Pharmaceutical describes thromboxane synthase inhibitors

Guangzhou Maxinovel Pharmaceuticals develops ALK tyrosine kinase receptor inhibitors

Shire offers overview of third quarter 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...